3282
Pharmacoeconomic evaluation of drugs used in enzyme replacement therapy mucopolysaccharidosis type II
As part of this work, a pharmacoeconomic study of drugs used in enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis (MPS) type II: idursulfase and idursulfase beta was carried out. As a result, it was found that the use of the drug idursulfase beta, is a more pharmacoeconomically beneficial treatment regimen for patients with MPS type II. Saving money when switching one patient from idursulfase to idursulfase beta makes up for one year - 7 377 746 rubles, for 5 years - 36 888 728 rubles. During the budget impact analysis, it was determined that an increase in the proportion of patients up to 50% in the idursulfase beta will make it possible to achieve an overall savings of 796 845 270 rubles. for 5 years. The missed opportunities analysis showed that an additional 28 patients could be treated with money saved as a result of a change in treatment strategy.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov A. Yu., Kostina E.O. Pharmacoeconomic evaluation of drugs used in enzyme replacement therapy mucopolysaccharidosis type II // Pharmacoeconomics: theory and practice. - 2019. - Vol.7, №2. - P. 10-15. DOI: https://doi.org/10.30809/phe.2.2019.2
Comments0